NCT07656922

Brief Summary

Migraine is a significant health problem due to its high prevalence and substantial contribution to disability. Individuals with migraine have been reported to exhibit myofascial trigger points, increased pain sensitivity, and altered muscle activation patterns, particularly in the trapezius muscles. As the upper and middle trapezius muscles play critical roles in scapular stability and movement, alterations in these muscles may affect scapular orientation and upper extremity function. However, studies investigating the relationship between trapezius muscle activation, scapular orientation, and upper extremity performance in individuals with migraine are limited. Therefore, this study aimed to compare trapezius muscle activation, scapular orientation, and upper extremity performance between individuals with and without migraine. We hypothesized that individuals with migraine would exhibit altered upper and middle trapezius muscle activation, impaired scapular orientation, and reduced upper extremity performance compared with healthy controls.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2026

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 15, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 18, 2026

Completed
13 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Completed
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2026

Completed
Last Updated

June 18, 2026

Status Verified

June 1, 2026

Enrollment Period

3 months

First QC Date

June 15, 2026

Last Update Submit

June 15, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Trapezius muscle activity

    Upper and middle trapezius muscle activations will be assessed on the dominant side using surface electromyography (sEMG). Following skin preparation, EMG sensors will be placed over the upper and middle trapezius muscles according to the recommendations of the Surface Electromyography for the Non-Invasive Assessment of Muscles (SENIAM). Resting muscle activity will be recorded prior to measurements to ensure signal quality. Muscle activations will first be recorded during maximal voluntary isometric contraction (MVIC) and subsequently during arm elevation in the scapular plane. EMG data will be analyzed using EMGworks software; signals will be filtered, processed using the root mean square (RMS) method, and normalized to each participant's MVIC values, expressed as %MVIC. Additionally, upper trapezius/middle trapezius activation ratios will be calculated, and muscle activation levels will be categorized according to predefined threshold values.

    Single assessment at baseline

Secondary Outcomes (3)

  • Scapular rotation

    Single assessment at baseline

  • Pain

    Single assessment at baseline

  • Upper extremity performance

    Single assessment at baseline

Study Arms (2)

Migraine

Control

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Adults diagnosed with migraine according to the ICHD-3 criteria

You may qualify if:

  • Aged 18-55 years
  • Diagnosed with migraine by a neurologist according to the ICHD-3 criteria
  • Experiencing at least 3 migraine attacks per month
  • Willing to participate and provide written informed consent

You may not qualify if:

  • Presence of other types of headache disorders
  • History of trauma, fracture, or surgery involving the cranio-cervical region, scapular region, or upper extremity
  • Presence of neurological or inflammatory rheumatic diseases
  • Presence of psychiatric disorders
  • Receiving physiotherapy or rehabilitation for migraine or the cervical, thoracic, or upper extremity regions within the past 6 months
  • Cognitive impairment affecting the understanding of test instructions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara Yıldırım Beyazıt University

Ankara, Çubuk, 06760, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Migraine Disorders

Condition Hierarchy (Ancestors)

Headache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 15, 2026

First Posted

June 18, 2026

Study Start

April 1, 2026

Primary Completion

July 1, 2026

Study Completion

July 15, 2026

Last Updated

June 18, 2026

Record last verified: 2026-06

Locations